The global U.S. cell therapy market size was valued at USD 2.88 billion in 2023 and is poised to grow from USD 3.49 billion in 2024 to USD 19.67 billion by 2033, growing at a CAGR of 21.18% in the forecast period (2024-2033).
The global U.S. cell therapy market size was valued at USD 2.88 billion in 2023 and is poised to grow from USD 3.49 billion in 2024 to USD 19.67 billion by 2033, growing at a CAGR of 21.18% in the forecast period (2024-2033).
Request PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.novaoneadvisor.com/report/sample/8445
Major factors contributing to this growth include the growing adoption of regenerative medicine, the rising number of clinical trials on cell therapies due to positive therapeutic outcomes, and the introduction of technological advancements in the market.
The U.S. cell therapy market accounted for a 56% share of the global cell therapy market in 2023. The increasing number of clinical studies on cellular therapies showcases a growing recognition of their potential across various medical conditions. Pharmaceutical companies are increasingly focusing on exploring and utilizing the therapeutic benefits of cells. Over 2,000 clinical trials were ongoing in the cell and gene therapy field as of January 2023, driven by positive outcomes in early-phase trials. These studies target conditions like cancer, autoimmune disorders, and degenerative diseases, aiming to maximize the therapeutic potential of different cell types, including stem cells and immune cells. Moreover, the advancement of genetic editing technologies like CRISPR-Cas9 enables precise modifications to cells’ genetic material thereby driving market growth.
In addition, the growing investments and funding for cell therapies are anticipated to enhance competition in the market. Academic and medical institutions are contributing to improving access to cell therapies. For instance, in October 2022, Cedars-Sinai received a 5-year, USD 8 million grant from California’s stem cell agency to establish a new clinic aimed at enhancing access to stem cell and gene therapies. This escalating investment and funding for cell therapies is projected to intensify competition within the market.
Key Takeaways:
- Autologous therapies segment dominated the market with a share of 91.9% in 2023.
- Allogenic therapies segment is projected to witness growth at the largest CAGR from 2024 to 2033
- The oncology segment held the market with a share of 92.5% in 2023.
- The dermatology segment is anticipated to grow at a significant CAGR from 2024 to 2033
What are the Importance of Cell Therapy?
Treatment of Various Diseases: Cell therapy offers promising avenues for treating a wide range of diseases and medical conditions. This includes degenerative disorders such as Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis, as well as autoimmune diseases like rheumatoid arthritis and type 1 diabetes. Additionally, cell therapy holds potential for treating cardiovascular diseases, spinal cord injuries, and certain types of cancer.
Regenerative Medicine: One of the most significant aspects of cell therapy is its role in regenerative medicine. Stem cells, in particular, have the remarkable ability to differentiate into various cell types and tissues in the body. This property allows them to regenerate damaged or diseased tissues and organs, offering hope for patients suffering from irreversible damage or degeneration.
Personalized Medicine: Cell therapy has the potential to revolutionize healthcare by offering personalized treatment approaches. By utilizing a patient’s own cells or cells specifically matched to the patient, the risk of rejection and the need for immunosuppressive drugs can be minimized. This tailored approach can lead to more effective and safer treatments with fewer side effects.
Reducing Reliance on Organ Transplants: Cell therapy may offer alternatives to traditional organ transplantation. Instead of relying on donated organs, which are often in short supply, patients could receive cellular therapies tailored to their specific needs. This could alleviate the burden on transplant waiting lists and reduce the risk of organ rejection.
Treatment of Genetic Disorders: Cell therapy holds promise for treating genetic disorders by replacing defective or missing genes with healthy ones. This approach, known as gene therapy, has the potential to cure genetic diseases at their root cause, offering hope to patients with conditions such as cystic fibrosis, muscular dystrophy, and certain types of cancer caused by genetic mutations.
Research and Development: Cell therapy serves as a vital tool for biomedical research, allowing scientists to better understand disease mechanisms, test new drugs, and develop innovative treatment strategies. By studying how different types of cells interact with the body and each other, researchers can uncover insights that contribute to advancements in medicine and healthcare.
Immediate Delivery Available, Get Full Access@
https://www.novaoneadvisor.com/report/checkout/8445
Therapy Type Insights
Autologous therapies segment dominated the market with a share of 91.9% in 2023. The growth is driven by the personalized nature and potential applications of these therapies in treating a wide range of diseases such as cancer, cardiovascular diseases, neurodegenerative diseases, and orthopedic injuries. Moreover, companies are actively developing cell therapies for cardiovascular diseases. For example, BIOCARDIA, INC. is working on CardiAMP Cell Therapy, an autologous cell therapy designed to treat individuals with ischemic heart failure. This trend of increasing these therapies is expected to drive demand over the forecast period.
Allogenic therapies segment is projected to witness growth at the largest CAGR from 2024 to 2033 owing to widespread use in developing innovative treatment approaches. Allogeneic cell therapies offer advantages over autologous cell therapies, such as immediate availability, scalability, and cost-effectiveness. Moreover, significant companies are expanding the production of allogeneic cell therapies. This trend is poised to drive market growth.
Therapeutic Area Insights
The oncology segment held the market with a share of 92.5% in 2023. The wide applications of cell therapy in the oncology sector are driving the growth. Various cell therapies, including CAR T cell therapies, TCR-based therapies, and allogeneic cord blood-based therapies, are utilized in the treatment of various cancers like blood cancer, melanoma, and multiple myeloma. Additionally, companies increasing their efforts to advance cell therapies for cancer treatment. These features are likely to expand market growth.
The dermatology segment is anticipated to grow at a significant CAGR from 2024 to 2033 owing to advancements in cell therapies for treating skin disorders. Furthermore, the increasing focus of companies on cell therapy for developing dermatological therapeutics is expected to boost the segment growth. For instance, in March 2024, SkinCure Oncology revealed new skin cancer treatment technology at the American Academy of Dermatology Annual Meeting in San Diego. This offers a noninvasive treatment option for non-melanoma skin cancer, providing a targeted and effective approach with high cure rates.
Recent Developments
- In January 2024, Cipla revealed a joint venture in the U.S. with Kemwell Biopharma and Manipal Education & Medical Group to globally develop and commercialize innovative cell therapy products.
- In February 2024, AstraZeneca announced the expansion of its manufacturing presence in the United States to speed up the advancement of next-generation cell therapy discovery and development.
- In February 2024, Children’s Hospital Los Angeles announced a grant of multi-year $6 million funding by the California Institute for Regenerative Medicine (CIRM) to produce novel stem cell strategies for treating children and teenagers with recurring solid tumors.
Some of the prominent players in the U.S. Cell Therapy Market include:
- Gilead Sciences, Inc.
- Selecta Bioscience
- Bristol-Myers Squibb Company
- CARGO Therapeutics, Inc.
- Johnson & Johnson
- Atara Biotherapeutics, Inc
- Nkarta, Inc
- Cellular Biomedicine Group, Inc
- Vertex Pharmaceuticals Incorporated
- Aurion Biotech
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Cell Therapy market.
By Therapy Type
- Allogeneic Therapies
- Stem Cell Therapies
- Hematopoietic Stem Cell Therapies
- Mesenchymal Stem Cell Therapies
- Non-Stem Cell Therapies
- Keratinocytes & Fibroblast-based Therapies
- Others
- Stem Cell Therapies
- Autologous Therapies
- T-Cell Therapies
- CAR T Cell Therapy
- T Cell Receptor (TCR)-based
- Others
- T-Cell Therapies
By Therapeutic Area
- Oncology
- Dermatology
- Others
U.S. Cell Therapy Market - Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall U.S. Cell Therapy market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Major factors contributing to this growth include the growing adoption of regenerative medicine, the rising number of clinical trials on cell therapies due to positive therapeutic outcomes, and the introduction of technological advancements in the market), opportunities (Growth opportunities in emerging countries), restraints (High capital investments and low cost-benefit ratio and unfavourable regulatory and reimbursement scenario), and challenges (Operational barriers) influencing the growth of the U.S. Cell Therapy market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the U.S. Cell Therapy market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the U.S. Cell Therapy market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the U.S. Cell Therapy market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Some of the key players in the U.S. cell therapy market include Gilead Sciences, Inc.; Selecta Bioscience; Bristol-Myers Squibb Company; CARGO Therapeutics, Inc.; Johnson & Johnson; Atara Biotherapeutics, Inc; Nkarta, Inc; Cellular Biomedicine Group, Inc; Vertex Pharmaceuticals Incorporated; Aurion Biotech.
Immediate Delivery Available | Buy This Premium Research
https://www.novaoneadvisor.com/report/checkout/8445
Call: USA: +1 650 460 3308 | IND: +91 87933 22019 |Europe: +44 2080772818
Email: sales@novaoneadvisor.com